Preliminary investigations into developing all-D Omiganan for treating Mupirocin-resistant MRSA skin infections

    loading  Checking for direct PDF access through Ovid


Staphylococcus aureus is the primary pathogen responsible for the majority of human skin infections, and meticillin-resistant S. aureus (MRSA) currently presents a major clinical concern. The overuse of Mupirocin, the first-line topical antibacterial drug over 30 years, has led to the emergence of Mupirocin-resistant MRSA, creating a clinical concern. The antimicrobial peptide Omiganan was touted to be a promising antibacterial drug candidate due to its rapid membrane-disrupting bactericidal mode of action, entering clinical trials in 2005 as a topical gel to prevent catheter site infections. However, drug development ceased in 2009 due to a lack of efficacy. We postulate this to be due to proteolytic degradation caused by endogenous human skin proteases. Herein, we tested our hypothesis using Omiganan and its all-D enantiomer in a human skin protease stability assay, followed by anti-MRSA activity assay against of a panel of clinical MRSA isolates, a bactericidal/static determination and a time-kill assay to gauge all-D Omiganan's potential for further topical antibacterial drug development.

Herein, we compared the skin protease stability and antibacterial activity of Omiganan, an antimicrobial peptide, to its all-D enantiomer. Results revealed that the latter was proteolytically more stable while possessing the same antibacterial potency, suggesting that the all-D peptide may be better suited as a topical drug development candidate.

Related Topics

    loading  Loading Related Articles